Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
OTC PK
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | 171.30K | 95.50K | 1.60K | 500.00 | 1.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 171.30K | 95.50K | 1.60K | 500.00 | 1.90K |
| Cost of Revenue | 48.60K | 38.40K | -- | -- | 0.00 |
| Gross Profit | 122.80K | 57.10K | 1.60K | 500.00 | 1.90K |
| SG&A Expenses | 460.00K | 615.20K | 777.40K | 1.19M | -4.87M |
| Depreciation & Amortization | 35.10K | 15.90K | 15.90K | 15.30K | -1.45M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 543.70K | 669.50K | 793.30K | 1.21M | -6.32M |
| Operating Income | -372.40K | -573.90K | -791.70K | -1.21M | 6.32M |
| Income Before Tax | -705.10K | -546.10K | -107.20K | -950.50K | -41.19M |
| Income Tax Expenses | -3.90K | 3.80K | -- | -- | -- |
| Earnings from Continuing Operations | -701.20K | -550.00K | -107.20K | -950.50K | -41.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 14.40K | -- | -- | -- | -277.10K |
| Net Income | -686.90K | -550.00K | -107.20K | -950.50K | -41.47M |
| EBIT | -372.40K | -573.90K | -791.70K | -1.21M | 6.32M |
| EBITDA | -365.00K | -558.00K | -775.80K | -1.19M | 6.33M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| Average Basic Shares Outstanding | 477.88M | 477.80M | 477.65M | 448.95M | 420.96M |
| Average Diluted Shares Outstanding | 477.88M | 477.80M | 477.65M | 448.95M | 420.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |